DLTx ASA and Blockchain Moon Acquisition Corp. Announce Business Combination on Saturday

DLTx ASA (OSX: DLTX) ("DLTx") and Blockchain Moon Acquisition Corp. (NASDAQ:BMAQU, BMAQ, BMAQW, BMAQR))) ("Blockchain Moon"), a special purpose acquisition vehicle, have entered into a business combination agreement pursuant to which Blockchain Moon will acquire all of the subsidiaries and substantially all of the assets of DLTx ASA.

DLTx ASA (OSX: DLTX) (“DLTx”) and Blockchain Moon Acquisition Corp. (NASDAQ:BMAQU, BMAQ, BMAQW, BMAQR)))) (“Blockchain Moon”), a special purpose acquisition vehicle, have entered into a business combination agreement pursuant to which Blockchain Moon will acquire all of the subsidiaries and substantially all of the assets of DLTx ASA. Upon the closing of the transaction, the new combined company of Blockchain Moon and such acquired subsidiaries and assets (the “Company”) is anticipated to be named DLTx Inc. and expects to trade under the symbol “DLTX” on the Nasdaq Global Market (the “Nasdaq”).

The Company will be based in the United States and will continue to specialize in protocols that provide predictable value both in utility and economics. The Company will build on DLTx’s strong track record in capitalizing on growth opportunities in the Web 3 space, including early investments in one of the largest industrial scale Bitcoin mining operations in North America, Filecoin cloud storage, and Decentralized Data Relay Services.

Total
0
Shares
Related Posts
Read More

Analysts’ Varied Perspectives On CytomX’s CX-904 Cancer Study: Safety Profile But Caution in Pancreatic Cancer

Initial data from CytomX Therapeutics' CX-904 Phase 1a study shows safety and anti-cancer activity in heavily pretreated patients with advanced metastatic solid tumors. Reductions observed, especially in pancreatic cancer, with stable disease maintained.

CTMX